John Cush
Rheumatology · Dallas, TXNPI 1265492680
Payments from drug & device makers
$3,944,864in general payments, 2019–2025
Across 663 payments — averaging $5950.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2.4M
- Novartis$953K
- E.r. Squibb & Sons, L.L.C.$398K
- UCB, Inc.$48K
- Swedish Orphan Biovitrum AB$35K
- Pfizer$34K
- plus $78K from 14 others
General payments by program year
19
20
21
22
23
24
25
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 153 | $2,398,694 |
| Novartis | 139 | $952,976 |
| E.r. Squibb & Sons, L.L.C. | 61 | $397,601 |
| UCB, Inc. | 42 | $48,445 |
| Swedish Orphan Biovitrum AB | 4 | $34,948 |
| Pfizer | 61 | $34,170 |
| Genentech USA, Inc. | 11 | $29,154 |
| Janssen Scientific Affairs, LLC | 117 | $16,016 |
| Amgen | 6 | $7,120 |
| Gilead | 7 | $6,636 |
| Eli Lilly | 1 | $5,600 |
| Lilly USA, LLC | 10 | $5,360 |
| UCB SA | 1 | $3,750 |
| Sanofi | 17 | $2,842 |
| Genentech, Inc. | 19 | $813 |
| Assertio Therapeutics, Inc. | 2 | $355 |
| Aurinia Pharma U.S., Inc. | 9 | $250 |
| AstraZeneca | 1 | $53 |
| Medline Industries LP | 1 | $47 |
| Boehringer Ingelheim | 1 | $33 |
How this compares
$3,944,864 in reported general payments places this provider in the 95th percentile of 512 rheumatology providers in Texas.
Other rheumatology in Dallas
- Stanley CohenDallas$1.9M
- David KarpDallas$788K
- Sharad LakhanpalDallas$718K
- Margarita FallenaDallas$488K
- Zoran KurepaDallas$483K
- Dianne PetroneDallas$437K
- Giovanni GeslaniDallas$415K
- Kathryn DaoDallas$381K
- Pedro CastilloDallas$379K
- Paul PickrellAustin$40.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.